Skip to main content
Contact Us
Subscribe
E-Edition
78°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Esperion Theraptc
(NQ:
ESPR
)
2.130
+0.040 (+1.91%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 24, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Esperion Theraptc
< Previous
1
2
3
Next >
Esperion to Report First Quarter 2024 Financial Results on May 7
April 23, 2024
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion Presents Important New Data from CLEAR Outcomes at ACC.24 Highlighting Value of NEXLETOL® (bempedoic acid) Tablets in Diverse Populations Including Women, Hispanics/Latinx and Patients with Obesity
April 07, 2024
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion to Ring Nasdaq Opening Bell Today, April 1, 2024
April 01, 2024
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion to Participate in 23rd Annual Needham Virtual Healthcare Conference
March 26, 2024
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion Announces Data from CLEAR Outcomes Sub-Groups as Poster Presentations, Moderated Session & Industry Expert Theatre to be Presented at ACC.24
March 25, 2024
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
U.S. FDA Approves Broad New Labels for Esperion’s NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use
March 22, 2024
From
Esperion Therapeutics
Via
Business Wire
U.S. FDA Approves Broad New Labels for NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use
March 22, 2024
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
CHMP Issues Positive Opinions For Both Bempedoic Acid And The Bempedoic Acid / Ezetimibe Fixed-Dose Combination Tablet As Treatments For Hypercholesterolemia And Significantly Reducing Cardiovascular Events
March 22, 2024
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion Reports Fourth Quarter and Full Year 2023 Financial Results
February 27, 2024
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
February 16, 2024
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion to Report Fourth Quarter and Full Year 2023 Financial Results on February 27
February 13, 2024
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
RFK, Esperion Therapeutics Announce 2024 Promotional Schedule
February 01, 2024
NEXLETOL and NEXLIZET to Ride Along RFK Mustangs in Four Races in 2024
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters’ Option to Purchase Additional Shares
January 23, 2024
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion Announces Pricing of $85.1 Million Public Offering of Common Stock
January 18, 2024
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion Announces Proposed Public Offering of Common Stock
January 18, 2024
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion and Daiichi Sankyo Europe Announce $125 Million Amendment to Their Collaboration, Including Resolution of Pending Litigation
January 03, 2024
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion to Participate in 42nd Annual J.P. Morgan Healthcare Conference
December 18, 2023
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
U.S. FDA Updates LDL-C Lowering Indication for Esperion’s NEXLETOL® (bempedoic acid) Tablet and NEXLIZET® (bempedoic acid and ezetimibe) Tablet
December 13, 2023
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion Presents CLEAR Outcomes Analysis of Inflammation as Predictor of Cardiovascular Risk at American Heart Association Scientific Sessions 2023
November 13, 2023
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Partners Announce TRANSFORM Trial to Evaluate Personalized Heart Disease Care Strategies at American Heart Association 2023
November 11, 2023
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
November 09, 2023
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion Reports Third Quarter 2023 Financial Results
November 07, 2023
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion to Participate in Jefferies London Healthcare Conference
October 31, 2023
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion to Report Third Quarter 2023 Financial Results on November 7
October 24, 2023
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
American College of Cardiology Program to Increase Cholesterol Screenings
September 12, 2023
From
Esperion Therapeutics, Inc.; The American College of Cardiology
Via
GlobeNewswire
Esperion to Participate in H.C. Wainwright 25th Annual Global Investment Conference
August 28, 2023
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion Presents Two CLEAR Outcomes Study Late-Breakers at European Society of Cardiology Congress 2023
August 26, 2023
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Two CLEAR Outcomes Study Late-Breakers Accepted at European Society of Cardiology (ESC) Congress 2023
August 11, 2023
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
August 08, 2023
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion Reports Second Quarter 2023 Financial Results
August 01, 2023
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.